Modulation of serum smooth muscle antibody levels by levamisole treatment in patients with oral lichen planus
Serum autoantibodies have been found in patients with oral lichen planus (OLP). This study evaluated whether OLP patients had significantly higher frequencies of serum smooth muscle antibody (SMA) than healthy control individuals, and assessed whether levamisole treatment could modulate the serum SM...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2013-06-01
|
| Series: | Journal of the Formosan Medical Association |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0929664613001198 |
| _version_ | 1811277624327012352 |
|---|---|
| author | Kai-Ming Wu Yi-Ping Wang Hung-Pin Lin Hsin-Ming Chen Jean-San Chia Andy Sun |
| author_facet | Kai-Ming Wu Yi-Ping Wang Hung-Pin Lin Hsin-Ming Chen Jean-San Chia Andy Sun |
| author_sort | Kai-Ming Wu |
| collection | DOAJ |
| description | Serum autoantibodies have been found in patients with oral lichen planus (OLP). This study evaluated whether OLP patients had significantly higher frequencies of serum smooth muscle antibody (SMA) than healthy control individuals, and assessed whether levamisole treatment could modulate the serum SMA levels in OLP patients.
Methods: This study used an indirect immunofluorescence technique to measure the baseline serum SMA levels in a group of 647 OLP patients and 53 controls. Ninety-five SMA-positive OLP patients were treated with levamisole under a regular follow-up schedule, and their serum SMA levels were measured after treatment.
Results: The frequencies of serum SMA in patients with OLP (21.9%), erosive OLP (EOLP, 21.6%), major EOLP (17.9%), minor EOLP (24.2%), and nonerosive OLP (24.4%) were all significantly higher than that (0%) in healthy controls (all p < 0.001). Of 142 SMA-positive OLP patients, 95 were treated with levamisole under a regular follow-up schedule. Treatment with levamisole for a period of 2–29 months (mean, 9.4 ± 6.0 months) effectively reduced the high mean serum SMA titer (71.0 ± 7.2) at baseline to an undetectable level (0) in all SMA-positive OLP patients, regardless of different initial serum SMA titers.
Conclusion: There was a significantly higher frequency of serum SMA (21.9%) in OLP patients than in healthy controls. Treatment with levamisole for 2–29 months significantly reduced the high serum SMA to an undetectable level, and significantly improved the signs and symptoms in all treated OLP patients. |
| first_indexed | 2024-04-13T00:20:07Z |
| format | Article |
| id | doaj.art-71f21c19992844f5b653c4f05ccd9222 |
| institution | Directory Open Access Journal |
| issn | 0929-6646 |
| language | English |
| last_indexed | 2024-04-13T00:20:07Z |
| publishDate | 2013-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of the Formosan Medical Association |
| spelling | doaj.art-71f21c19992844f5b653c4f05ccd92222022-12-22T03:10:48ZengElsevierJournal of the Formosan Medical Association0929-66462013-06-01112635235710.1016/j.jfma.2013.03.003Modulation of serum smooth muscle antibody levels by levamisole treatment in patients with oral lichen planusKai-Ming Wu0Yi-Ping Wang1Hung-Pin Lin2Hsin-Ming Chen3Jean-San Chia4Andy Sun5Department of Dentistry, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, TaiwanDepartment of Dentistry, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, TaiwanDepartment of Dentistry, China Medical University Hospital, College of Medicine, China Medical University, Taichung, TaiwanDepartment of Dentistry, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, TaiwanDepartment of Dentistry, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, TaiwanDepartment of Dentistry, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, TaiwanSerum autoantibodies have been found in patients with oral lichen planus (OLP). This study evaluated whether OLP patients had significantly higher frequencies of serum smooth muscle antibody (SMA) than healthy control individuals, and assessed whether levamisole treatment could modulate the serum SMA levels in OLP patients. Methods: This study used an indirect immunofluorescence technique to measure the baseline serum SMA levels in a group of 647 OLP patients and 53 controls. Ninety-five SMA-positive OLP patients were treated with levamisole under a regular follow-up schedule, and their serum SMA levels were measured after treatment. Results: The frequencies of serum SMA in patients with OLP (21.9%), erosive OLP (EOLP, 21.6%), major EOLP (17.9%), minor EOLP (24.2%), and nonerosive OLP (24.4%) were all significantly higher than that (0%) in healthy controls (all p < 0.001). Of 142 SMA-positive OLP patients, 95 were treated with levamisole under a regular follow-up schedule. Treatment with levamisole for a period of 2–29 months (mean, 9.4 ± 6.0 months) effectively reduced the high mean serum SMA titer (71.0 ± 7.2) at baseline to an undetectable level (0) in all SMA-positive OLP patients, regardless of different initial serum SMA titers. Conclusion: There was a significantly higher frequency of serum SMA (21.9%) in OLP patients than in healthy controls. Treatment with levamisole for 2–29 months significantly reduced the high serum SMA to an undetectable level, and significantly improved the signs and symptoms in all treated OLP patients.http://www.sciencedirect.com/science/article/pii/S0929664613001198levamisoleoral lichen planussmooth muscle antibody |
| spellingShingle | Kai-Ming Wu Yi-Ping Wang Hung-Pin Lin Hsin-Ming Chen Jean-San Chia Andy Sun Modulation of serum smooth muscle antibody levels by levamisole treatment in patients with oral lichen planus Journal of the Formosan Medical Association levamisole oral lichen planus smooth muscle antibody |
| title | Modulation of serum smooth muscle antibody levels by levamisole treatment in patients with oral lichen planus |
| title_full | Modulation of serum smooth muscle antibody levels by levamisole treatment in patients with oral lichen planus |
| title_fullStr | Modulation of serum smooth muscle antibody levels by levamisole treatment in patients with oral lichen planus |
| title_full_unstemmed | Modulation of serum smooth muscle antibody levels by levamisole treatment in patients with oral lichen planus |
| title_short | Modulation of serum smooth muscle antibody levels by levamisole treatment in patients with oral lichen planus |
| title_sort | modulation of serum smooth muscle antibody levels by levamisole treatment in patients with oral lichen planus |
| topic | levamisole oral lichen planus smooth muscle antibody |
| url | http://www.sciencedirect.com/science/article/pii/S0929664613001198 |
| work_keys_str_mv | AT kaimingwu modulationofserumsmoothmuscleantibodylevelsbylevamisoletreatmentinpatientswithorallichenplanus AT yipingwang modulationofserumsmoothmuscleantibodylevelsbylevamisoletreatmentinpatientswithorallichenplanus AT hungpinlin modulationofserumsmoothmuscleantibodylevelsbylevamisoletreatmentinpatientswithorallichenplanus AT hsinmingchen modulationofserumsmoothmuscleantibodylevelsbylevamisoletreatmentinpatientswithorallichenplanus AT jeansanchia modulationofserumsmoothmuscleantibodylevelsbylevamisoletreatmentinpatientswithorallichenplanus AT andysun modulationofserumsmoothmuscleantibodylevelsbylevamisoletreatmentinpatientswithorallichenplanus |